Sept 14 (Reuters) – AC Immune, the Swiss biotech company
working on treatments for Alzheimer’s disease, has set the
pricing band for its keenly awaited U.S. initial public
offering, valuing the firm…
The post UPDATE 1-Swiss Alzheimer’s biotech AC Immune eyes $700 mln IPO valuation appeared first on NASDAQ.